Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE ...
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...
Mersana Therapeutics (MRSN) announced the FDA recently granted an additional Fast Track designation to XMT-1660. The new Fast Track ...
Hosted on MSN2d
Russia's losses in Ukraine as of January 8: +1,660 troops, 19 drones, 19 artillery systemsOver the last day, from January 7 to January 8, the Russian military lost 1,660 soldiers, 16 armored combat vehicles, and 19 ...
The Russian invasion forces are estimated to have suffered 801,670 combat casualties since the outset of the full-scale ...
If you still need to get rid of that old Christmas tree, the city of Winston-Salem has multiple options available. Earlier ...
Authorities are asking for the public’s help identifying a suspect accused of a stabbing in Dorchester on Thursday night.
The Dell XPS 14 9440, a new model following the laptop line's reset, is on sale from Dell with a $400 discount. Get this stylish and powerful device for $1,660.
Dunzo had engaged in talks with Swiggy and Tata's BigBasket regarding a potential buyout, but these discussions ultimately ...
Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...
The National Telecommunications and Information Administration (NTIA) has published a Notice and Request for Comment (RFC) on the potential impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback